RCM
CASC

Rotella Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Rotella Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,320
Closed -$97K – 724
2015
Q2 		$97K Buy
+4,320
New +$68.3K 0.08% 283
2014
Q3 		– Sell
-3,170
Closed -$62K – 445
2014
Q2 		$62K Sell
3,170
-400
-11% -$7.06K 0.05% 291
2014
Q1 		$64K Buy
+3,570
New +$58.6K 0.08% 151

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Rotella Capital Management's CASC Position: Q3 2015 in Review

Rotella Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 4,320 shares — an estimated $97K sold.

Rotella Capital Management first reported a position in CASC in Q1 2014 and held it in 3 quarters. The position peaked at $97K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • Rotella Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 4,320 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $97K.
  • Rotella Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • Rotella Capital Management's Cascadian Therapeutics, Inc. position peaked at $97K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.